

Index

ABBREVIATED NEW DRUG SUBMISSION (ANDS)

Informational requirements, **1:3**
Supplemental, **1:7**

ACCESS TO INFORMATION ACT

New drug approval process, **1:4**

ADVERTISING LIFE SCIENCES PRODUCTS

Generally, **3:1 et seq.**
Advertising Standards Canada (ASC), **3:3**
Consumer advertising
 generally, **3:4**
 natural health products, **3:4**
 non-prescription drugs, **3:4**
 prescription drugs, **3:4**
Definitions and classifications, **3:2**
False, misleading, deceptive advertising,
 3:2
Health Canada, **3:3**
Introduction, **3:1**
Labelling requirements, (prescription,
 non-prescription, NHPs), **3:4**
Medical devices, **3:4**
Regulatory control, **3:3**
Vaccines, **3:4**

ADVERTISING STANDARDS CANADA (ASC)

Generally, **3:3**

BIOLOGIC AND GENERIC THERAPIES DIRECTORATE (BGTD)

Generally, **1:5**
Regulatory control, **3:3**
Submissions and review, **1:8**

BIOLOGICS

Regulation of products and, **1:5**

CANADIAN ASSOCIATION OF MEDICAL PUBLISHERS (CAMP)

Marketing to healthcare professionals, **3:5**

CANADIAN INTELLECTUAL PROPERTY OFFICE (CIPO)

Generally, **6:1 et seq.**
Trademarks and, **10:1**

CANADIAN INTERNET REGISTRATION AUTHORITY (CIRA)

Domain names and, **10:2**

CANADIAN MEDICAL ASSOCIATION

Marketing to healthcare professionals, **3:5**
Provincial medical associations, **3:5**

CANNABIS

Cannabis Act, **2:1 et seq.**
Drugs containing cannabis, **2:3**
 advertising and promotion, **2:3**
Importation and exportation of, **2:5**
Medical cannabis
 generally, **2:2**
 access to, **2:2**
 advertising and promotion, **2:2**
 licence for sale of cannabis, **2:2**
 packaging and labelling, **2:2**
 personal possession limits, **2:2**
Overview of access to cannabis, **2:1**
Regulation of products, **2:1 et seq.**
Test kits, **2:4**

CLINICAL TRIAL APPLICATION (CTA)

Amendments, of, **1:9**
Regulation of products, **1:9**

CLINICAL TRIALS

Generally, **1:9**
Human subjects
 generally, **1:12**
 authorization, **1:12**
 sponsor obligations, **1:12**
 suspension or cancellation, **1:12**
Natural health products, **1:12**

COMPETITION ACT

Advertising and labelling, **3:1, 3:4**

**CONTROLLED DRUGS AND
SUBSTANCES ACT**Regulation of products, **1:1****CONVENTION ON BIOLOGICAL
DIVERSITY (CBD)**Canada's international obligations, **5:5****DATA PROTECTION**Generally, **9:1 et seq.**Canada, in, **9:4**Canada's international obligations, **9:2**Other countries, in, **9:3****DISPUTE SETTLEMENT****UNDERSTANDING (DSU)**Mechanisms under TRIPS and NAFTA,
5:6**DRUG IDENTIFICATION NUMBER
(DIN)**Marketing approval, **1:3****DRUGS**Biologics, **1:5**Changes to new drugs once approved, **1:7**Clinical trials, **1:9**Drug-medical device combination
products, **1:11**Drugs containing cannabis, **2:3**
advertising and promotion, **2:3**Genetic therapies, **1:5**

Marketing approval

generally, **1:3**drug identification number (DIN), **1:3**notice of compliance, **1:3**

standards for establishments

generally, **1:3**establishment licences, **1:3**good manufacturing practices,
application of, **1:3**

Natural health products (NHP)

generally, **1:12**

clinic trials involving human subjects

generally, **1:12**authorization, **1:12**sponsor obligations, **1:12**suspension or cancellation, **1:12**good manufacturing practices, **1:12**history of NHP legislation, **1:12**labelling and packaging, **1:12, 3:4**

product licences

generally, **1:12****DRUGS—Cont'd**Natural health products (NHP)—Cont'd
product licences—Cont'damending product licence, **1:12**application for, **1:12**cancellation or suspension, **1:12**reporting obligations on licensees,
1:12scope of NHP legislation, **1:12**site licences, **1:12**New drug approval process, **1:4**

Non-prescription drugs

advertising and promotion, **3:4**labelling requirements, **3:4**Post-market surveillance, **1:6**

Prescription drugs

labelling requirements, **3:4**Radiopharmaceuticals, **1:5**Regulation of products, **1:1 et seq.**Sale of, **1:2**Submission and review process, **1:8**Supplemental abbreviated new submis-
sions, **1:7, 5:7****FOOD AND DRUG REGULATIONS**

Clinical trials

amendment to application, **1:9**application, **1:9**Data protection and, **9:4**

Notice of Compliance (NOC) Regulations

generally, **8:3**framework, **8:3**policy concerns, **8:2**Patent listing submission, nature of, **8:5****FOOD AND DRUGS ACT**

See also DRUGS

Biologics, **1:5**Clinical trials, **1:9**Genetic therapies, **1:5**Medical devices, **1:10**Radiopharmaceuticals, **1:5**Regulation of products, **1:1 et seq.**

Regulations under

clinical trials

amendment to application, **1:9**application, **1:9**data protection and, **9:4**framework, **8:3**policy concerns, **8:2**

INDEX

FOOD AND DRUGS ACT—Cont'd

- Regulations under—Cont'd
 - Notice of Compliance (NOC) Regulations, **8:3**
 - patent listing submission, nature of, **8:5**

GENERAL AGREEMENT ON TARIFFS AND TRADE

- Canadian international obligations, **5:2, 9:2**

HEALTH CANADA

- Biologic and Genetic Therapeutics Directorate (BGTD), **3:3**
- Biologics, **1:5**
- Genetic therapies, **1:5**
- Health Products and Food Branch, **3:3**
- Licensing service division, **1:8**
- Marketed Health Products Directorate, **3:3**
- Radiopharmaceuticals, **1:5**
- Regulatory control, advertising life science products, **3:3**
- Therapeutic Products Directorate, **1:8, 1:11**

HEALTH CARE PROFESSIONALS

- Marketing, to
 - generally, **3:5**
 - Innovative Medicines Canada (IMC), **3:5**
 - pharmaceutical advertising advisory board (PAAB), **3:5**
 - provincial medical associations, **3:5**

INCOME TAX ACT

- Generally, **13:1 et seq.**

INNOVATIVE MEDICINES CANADA (IMC)

- Generally, **3:5**

INTERNATIONAL TRADE

OBLIGATIONS

- Generally, **5:1**
- Canada's previous obligations
 - Berne Convention for the Protection of Literary and Artistic Works, **5:2**
 - Canada-US Free Trade Agreement, **5:2**
 - General Agreement on Tariffs and Trade, **5:2**
 - Paris Convention for the Protection of Industrial Property, **5:2**
- CETA, **5:7**

INTERNATIONAL TRADE

OBLIGATIONS—Cont'd

- Dispute settlement mechanisms
 - generally, **5:6**
 - NAFTA, **5:6, 9:2**
 - TRIPS, **5:6, 9:2**
- Implementation in Canada
 - generally, **5:4**
 - Bill C-22, **5:4**
 - Bill C-91, **5:4**
 - legislation, **5:4**
- Life sciences products, relevant provisions re
 - basic obligations, **5:5**
 - data protection, **5:5**
 - enforcement, **5:5**
 - exceptions, limited, **5:5**
 - licensing, compulsory, **5:5**
 - non-discrimination, **5:5**
 - patentability, **5:5**
 - patent protection, term of, **5:5**
 - patent rights, **5:5**
- Negotiations
 - NAFTA, **5:3**
 - TRIPS, **5:3**
- Trans-Pacific Partnership (TPP), **5:8**

LICENCES

- Establishment
 - drugs, **1:3**
 - medical devices, **1:10**
- Product
 - generally, **1:12**
 - amending product licence, **1:12**
 - application for, **1:12**
 - cancellation or suspension, **1:12**
 - reporting obligations on licensees, **1:12**
- Site licences, **1:12**

MARKETED HEALTH PRODUCTS DIRECTORATE

- Marketing, advertising and labelling, **3:3**

MARKETING

- See also **ADVERTISING AND PROMOTION OF LIFE SCIENCES PRODUCTS**
- Healthcare professionals, to
 - generally, **3:5**
 - Innovative Medicines Canada (IMC), **3:5**

MARKETING—Cont'd

- Healthcare professionals, to—Cont'd
 - pharmaceutical advertising advisory board, **3:5**
 - provincial medical associations, **3:5**
- Labelling requirements
 - natural health products, **1:12**
 - non-prescription drugs, **3:4**
 - prescription drugs, **3:4**

MEDICAL CANNABIS

- See also CANNABIS
- Access to, **2:2**
- Advertising and promotion, **2:2, 3:4**
- Licence for sale of cannabis, **2:2**
- Packaging and labelling, **2:2**
- Personal possession limits, **2:2**

MEDICAL DEVICES

- Generally, **1:10**
- Advertising and promotion, **3:4**
- Approval to sell in Canada, **1:10**
- Establishment licences, **1:10**
- Investigational testing, **1:10**
- Reporting obligations, **1:10**
- Special access, **1:10**

NATURAL HEALTH PRODUCTS (NHP)

- Generally, **1:12**
- Clinic trials involving human subjects
 - generally, **1:12**
 - authorization, **1:12**
 - sponsor obligations, **1:12**
 - suspension or cancellation, **1:12**
- Good manufacturing practices, **1:12**
- History of NHP legislation, **1:12**
- Labelling and packaging, **1:12**
- Product licences
 - generally, **1:12**
 - amending product licence, **1:12**
 - application for, **1:12**
 - cancellation or suspension, **1:12**
 - reporting obligations on licensees, **1:12**
- Scope of NHP legislation, **1:12**
- Site licences, **1:12**

NEW DRUG SUBMISSIONS

- Abbreviated, **5:7**
- Access to Information Act, **1:4**
- Patent listing and, **8:5**

NOTICE OF COMPLIANCE

- See also PATENTED MEDICINES (NOC REGULATIONS)
- Notice of compliance regulations
 - generally, **8:1**
 - framework of, **8:3**
 - policy concerns addressed by, **8:2**

PATENTABILITY REQUIREMENTS

- See also PATENT LAW
- Double patenting, **6:3**
- Life forms, patentability of
 - generally, **6:5**
 - Abitibi case, **6:5**
 - deposit of biological materials, **6:5**
 - Harvard Mouse case, **6:5**
 - Monsanto case, **6:5**
- Novelty and inventiveness, **6:3**
- Overlapping subject matter, **6:3**
- Sufficiency of specification, **6:3**
- Utility, **6:3**

PATENTED MEDICINES (NOC REGULATIONS)

- Addressing listed patents
 - generally, **8:7**
 - confidentiality, **8:7**
 - invalidity allegations, **8:7**
 - non-infringement allegations, **8:7**
 - notice of allegation
 - generally, **8:7**
 - other challenges, **8:7**
 - sufficiency of, **8:7**
- Certificates of supplementary protection
 - generally, **8:6**
 - CSP term, **8:6**
 - eligibility for, **8:6**
- Initiating proceedings
 - generally, **8:8**
 - abuse of process, **8:8**
 - appealing a ruling, **8:9**
 - burden of proof, **8:8**
 - indirect infringement, **8:8**
 - on or after September 21, 2017, **8:8**
 - prior to September 21, 2017, **8:8**
 - Section 8 damages, **8:10**
 - summary dismissal, **8:8**
 - time period, **8:8**
- Notice of compliance regulations
 - generally, **8:1**
 - framework of, **8:3**

PATENTED MEDICINES (NOC REGULATIONS)—Cont'd

- Notice of compliance regulations—Cont'd
 - policy concerns addressed by, **8:2**
- Patent listing
 - generally, **8:5**
 - challenging, **8:5**
 - maintenance of patent register, **8:5**
 - nature of submission, **8:5**
 - timing requirements, **8:5**

PATENT ENFORCEMENT

- Generally, **7:1**
- Defences to infringement
 - generally, **7:6**
 - non-inducement to infringe, **7:6**
 - non-infringement
 - generally, **7:6**
 - invalidity, **7:6**
 - licence, **7:6**
- Experimental testing, **7:8**
- Expert witnesses
 - generally, **7:7**
 - definition of, **7:7**
 - qualifications of, **7:7**
 - role of, **7:7**
- Infringement
 - generally, **7:4**
 - checklist before commencing infringement suit
 - generally, **7:5**
 - additional circumstances, **7:5**
 - assessment, **7:5**
 - basic information, **7:5**
 - relief sought, **7:5**
 - defences to, **7:6**
 - definition, **7:4**
 - proof of, **7:4**
 - types, **7:4**
- Monopoly rights
 - generally, **7:2**
 - actual rights, **7:2**
 - duration of rights, **7:2**
 - remedies
 - generally, **7:2**
 - accounting of profits, **7:2**
 - damages, **7:2**
 - delivery up, **7:2**
 - injunctions, **7:2**

PATENT ENFORCEMENT—Cont'd

- Patent infringer, proceedings against
 - generally, **7:3**
 - litigation, **7:3**
- litigation
 - checklist before commencing, **7:5**
- pre-litigation
 - generally, **7:3**
 - alternative dispute resolution, **7:3**
 - cease and desist letter, **7:3**

PATENT INFRINGEMENT

- See also PATENT ENFORCEMENT
- Generally, **7:4**
- Checklist before commencing infringement suit
 - generally, **7:5**
 - additional circumstances, **7:5**
 - assessment, **7:5**
 - basic information, **7:5**
 - relief sought, **7:5**
- Defences to
 - generally, **7:6**
 - non-inducement to infringe, **7:6**
 - non-infringement
 - generally, **7:6**
 - invalidity, **7:6**
 - licence, **7:6**
- Definition, **7:4**
- Proof of, **7:4**
- Types, **7:4**

PATENT LAW

- Generally, **6:1 et seq.**
- DNA, RNA, and antibodies, patentability of
 - generally, **6:6**
 - antibodies, **6:6**
 - background, **6:6**
 - disclosure, **6:6**
- Fertilized eggs, patentability of, **6:7**
- Infringement
 - see also PATENT INFRINGEMENT
 - defences to, **7:6**
 - invalidity, **7:6**
 - licence, **7:6**
 - non-inducement to infringe, **7:6**
 - non-infringement, **7:6**
- Life forms, patentability of
 - generally, **6:5**

PATENT LAW—Cont'd

- Life forms, patentability of—Cont'd
 - Abitibi case, **6:5**
 - deposit of biological materials, **6:5**
 - Harvard Mouse case, **6:5**
 - Monsanto case, **6:5**
- Organ and tissues, **6:7**
- Patentability requirements
 - generally, **6:3**
 - double patenting, **6:3**
 - novelty and inventiveness, **6:3**
 - overlapping subject matter, **6:3**
 - sufficiency of specification, **6:3**
 - utility, **6:3**
- Patent application
 - prosecution, of, **6:2**
- Prosecution of patent application
 - generally, **6:2**
 - action, final, **6:2**
 - allowance and issuance, **6:2**
 - amendment after allowance, **6:2**
 - appeals, **6:2**
 - convention priority, **6:2**
 - entity status, **6:2**
 - examination of application, **6:2**
 - filing prior art, **6:2**
 - maintenance fees, **6:2**
 - national entry, **6:2**
 - official filing date, **6:2**
 - ownership, **6:2**
 - publication, **6:2**
 - public disclosure restrictions, **6:2**
 - re-examination of patents, **6:2**
 - reissue and disclaimer, **6:2**
 - request for examination, **6:2**
- Stem cells, patentability of, **6:7**

**PHARMACEUTICAL ADVERTISING
ADVISORY BOARD (PAAB)**

- Marketing to healthcare professionals, **3:5**

**PHARMACEUTICAL PRICING AND
MARKET ACCESS**

- Patented medicine prices review board
 - generally, **4:1 to 4:8**
 - compendium of guidelines, policies and procedures, **4:3**
 - constitutionality, **4:5**
 - mandate, jurisdiction and process, **4:4**
 - mandatory reporting requirements, **4:6**
 - proposed new regulations, **4:7**

**PHARMACEUTICAL PRICING AND
MARKET ACCESS—Cont'd**

- Patented medicine prices review board
 - Cont'd
 - provincial pricing issues, **4:8**
 - statutory framework
 - generally, **4:2**
 - excessive pricing provisions, **4:1 to 4:8**
 - process provisions, **4:1 to 4:8**
 - Reporting requirements, **4:1 to 4:8**

PRIVACY LAW

- Generally, **12:1 et seq.**
- Breaches and breach response, **12:6**
- Compliance, **12:7**
- Fundamental principles, **12:3**
- Human subject research, **12:5**
- Legislative framework, **12:2**
- Organizational privacy vigilance, **12:7**
- Personal health information, **12:4**

PRODUCT LIABILITY

- Generally, **11:1 et seq.**
- Causation, **11:3**
- Class actions, **11:6**
- Contract and statutory claims, **11:5**
- Damages, **11:7**
- Innovator liability, generic drug sales, **11:4**
- Limitation periods, **11:8**
- Negligence claims
 - generally, **11:2**
 - design defect claim, **11:2**
 - failure to warn claim, **11:2**
 - manufacturing defect claim, **11:2**
- Procedural issues, **11:9**
- Québec law principles, **11:10**

**SUPPLEMENTAL ABBREVIATED
NEW DRUG SUBMISSION
(SANDS)**

- Generally, **1:7, 5:7**

TAX ISSUES

- Generally, **13:1**
- Goods and Services Tax (GST), **13:5**
- Harmonized Sales Tax (HST), **13:5**
- Québec Sales Tax (QST), **13:5**
- Scientific research and experimental development
 - generally, **13:2**

INDEX

TAX ISSUES—Cont'd

- Scientific research and experimental development—Cont'd
 - advancement, **13:2**
 - content, **13:2**
 - tax credits, **13:2**
 - uncertainty, **13:2**
- Transfer pricing, **13:3**
- Withholding tax, **13:4**

THERAPEUTIC PRODUCTS

DIRECTORATE (TPD)

- See also HEALTH CANADA
- Generally, **1:8, 1:11**

TRADEMARKS AND DOMAIN NAMES

- Generally, **10:1 et seq.**
- Domain names
 - generally, **10:2**
 - dot-ca, **10:2**
 - recourse for aggrieved trademark owner, **10:2**

TRADEMARKS AND DOMAIN NAMES

—Cont'd

- Trademarks
 - generally, **10:1**
 - licences, **10:1**
 - opposition process, **10:1**
 - pharmaceutical trade dress protection
 - generally, **10:1**
 - application requirements, **10:1**
 - distinctiveness of, **10:1**
 - functionality of, **10:1**
 - registration and renewal, **10:1**
 - registration process (prior to proposed changes)
 - generally, **10:1**
 - application requirements, **10:1**
 - registrability, examination for, **10:1**
 - regulatory issues, intersection of, **10:1**
- WORLD INTELLECTUAL PROPERTY OFFICE (WIPO)**
 - Patentability of DNA, RNA and antibodies, **6:6**